Exploratory long-term follow-up analysis of phase III POLARIX study indicated a positive trend in OS in favour of Polivy in combo with R-CHP for people with first-line large B-cell lymphoma (DLBCL)

Roche announced data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy (polatuzumab vedotin) in combination with MabThera/Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people [...]